$-0.27 EPS Expected for Oramed Pharmaceuticals, Inc. (ORMP)

June 20, 2017 - By Henry Gaston

 $ 0.27 EPS Expected for Oramed Pharmaceuticals, Inc. (ORMP)
Investors sentiment increased to 1.25 in 2016 Q4. Its up 0.81, from 0.44 in 2016Q3. It improved, as 1 investors sold Oramed Pharmaceuticals, Inc. shares while 3 reduced holdings. 4 funds opened positions while 1 raised stakes. 109,206 shares or 33.39% less from 163,943 shares in 2016Q3 were reported.
Jfs Wealth Ltd Limited Liability Company reported 0% of its portfolio in Oramed Pharmaceuticals, Inc. (NASDAQ:ORMP). Morgan Stanley accumulated 15,860 shares. Barclays Public Ltd Llc accumulated 29,925 shares. Deutsche National Bank & Trust Ag reported 5 shares or 0% of all its holdings. Wells Fargo & Mn holds 8,000 shares. National Bank & Trust Of America Corp De holds 917 shares. Kcg owns 13,910 shares. Sunbelt Incorporated holds 0% of its portfolio in Oramed Pharmaceuticals, Inc. (NASDAQ:ORMP) for 290 shares. State Bank Of Montreal Can has invested 0% in Oramed Pharmaceuticals, Inc. (NASDAQ:ORMP). Financial Architects accumulated 2,000 shares. Finemark Retail Bank has invested 0% in Oramed Pharmaceuticals, Inc. (NASDAQ:ORMP). Tower Rech Ltd Company (Trc) reported 0% in Oramed Pharmaceuticals, Inc. (NASDAQ:ORMP). Creative Planning has 2,000 shares. Pnc Services reported 21,200 shares. Plante Moran Fincl Advsr Limited Com holds 0% or 300 shares in its portfolio.

Analysts await Oramed Pharmaceuticals, Inc. (NASDAQ:ORMP) to report earnings on July, 5. They expect $-0.27 earnings per share, down 80.00 % or $0.12 from last year’s $-0.15 per share. After $-0.24 actual earnings per share reported by Oramed Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts 12.50 % negative EPS growth. It closed at $7.63 lastly. It is down 2.79% since June 20, 2016 and is uptrending. It has underperformed by 13.91% the S&P500.

Oramed Pharmaceuticals, Inc. (NASDAQ:ORMP) Ratings Coverage

Among 3 analysts covering Oramed Pharmaceuticals (NASDAQ:ORMP), 3 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Oramed Pharmaceuticals had 5 analyst reports since August 14, 2015 according to SRatingsIntel. Rodman & Renshaw initiated Oramed Pharmaceuticals, Inc. (NASDAQ:ORMP) on Friday, October 2 with “Buy” rating. The stock has “Buy” rating by H.C. Wainwright on Thursday, October 1. FBR Capital initiated the stock with “Outperform” rating in Thursday, November 19 report. The company was upgraded on Friday, August 14 by Zacks. H.C. Wainwright maintained Oramed Pharmaceuticals, Inc. (NASDAQ:ORMP) rating on Tuesday, December 1. H.C. Wainwright has “Buy” rating and $25 target.

Oramed Pharmaceuticals Inc. is engaged in the field of oral delivery solutions for drugs and vaccines presently delivered via injection. The company has market cap of $104.03 million. Oramed’s flagship product, an orally ingestible insulin capsule in phase II clinical trials, is focused on the treatment of diabetes. It currently has negative earnings. The Firm is developing orally ingestible protein oral delivery (POD) technology for the delivery of drugs presently administered by way of injection.

More notable recent Oramed Pharmaceuticals, Inc. (NASDAQ:ORMP) news were published by: Seekingalpha.com which released: “Does Oramed Pharmaceuticals Pass The Smell Test?” on May 23, 2014, also Prnewswire.com with their article: “SHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Oramed …” published on June 05, 2017, Seekingalpha.com published: “Oramed: Progress On Oral Insulin Pill” on July 27, 2016. More interesting news about Oramed Pharmaceuticals, Inc. (NASDAQ:ORMP) were released by: Quotes.Wsj.com and their article: “News Oramed Pharmaceuticals Inc.ORMP” published on February 11, 2013 as well as Seekingalpha.com‘s news article titled: “Oramed: The Atypical Biotechnology Company With Great Upside Potential” with publication date: July 01, 2016.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.